Summaries of the Section H (HML) update

Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.

The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule. 

The changes will be published in the Online HML(external link) around the 23rd of this month and are effective from next month. 

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

18 November 2025 - preview of changes for December 2025

Pharmaceutical

Change

Adrenaline (DBL Adrenaline) inj 1 in 1,000, 1 ml ampoule, 50 inj pack

delisted 1 December 2025

Aflibercept (Eylea) inj 40 mg per ml, 0.1 ml vial

amended restriction criteria

Bevacizumab (ocular) (Avastin) inj 25 mg per ml, 4 ml vial 

new listing (p’code 2211181)

Bevacizumab (ocular) inj 25 mg per ml, 4 ml vial (Avastin) and inj 25 mg per ml, 16 ml vial

amended restriction criteria

Buprenorphine with naloxone (Buprenorphine
Naloxone BNM) tab 2 mg with naloxone 0.5 mg

addition of PSS

Buprenorphine with naloxone (Buprenorphine
Naloxone BNM) tab 8 mg with naloxone 2 mg

price decrease and addition of PSS

Carboplatin (DBL Carboplatin) inj 10 mg per ml, 45 ml vial

to be delisted 1 January 2026

 

Cefalexin cap 250 mg (Cefalexin Lupin) and cap 500 mg (Cefalexin Sandoz) 

Brand change

New listing and addition of PSS

  • Cap 250 mg (Cefalexin Lupin) (p’code 2712148)
  • Cap 500 mg (Cefalexin Sandoz) (p’code 2712628)

Cephalexin ABM to be delisted 1 July 2026

Citalopram hydrobromide (Celapram) tab 20 mg

price increase and addition of PSS

Covid-19 vaccine (Comirnaty (LP.8.1))

  • inj 3 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml, 0.48 ml multi-dose vial; infant vaccine, yellow cap
  • inj 10 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml, 0.48 ml single-dose vial; paediatric vaccine, light blue cap
  • inj 30 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml, pre-filled syringe; adult vaccine

new listing

  • Inj 3 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml, 0.48 ml multi-dose vial; infant vaccine, yellow cap (p’code 2717107)
  • Inj 10 mcg SARS-CoV-2 spike
    protein (mRNA) LP.8.1 per 0.3 ml, 0.48 ml single-dose vial; paediatric vaccine, light blue cap (p’code 2717115)
  • Inj 30 mcg SARS-CoV-2 spike
    protein (mRNA) LP.8.1 per 0.3 ml,
    pre-filled syringe; adult vaccine (p’code 2717123)

Covid-19 vaccine (Comirnaty Omicron (JN.1))

  • inj 3 mcg bretovameran per 0.3 ml, 0.48 ml vial; infant vaccine, yellow cap
  • inj 10 mcg bretovameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap
  • inj 30 mcg bretovameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap

to be delisted 1 June 2026

Crizotinib (Xalkori) cap 200 mg and 250 mg

amended restriction criteria

Dabrafenib (Tafinlar) cap 50 mg and 75 mg

amended restriction criteria

Denosumab inj 120 mg per 1.7 ml vial (Xgeva) and inj 60 mg per 1 ml prefilled syringe (Prolia)

price decrease

Docusate sodium with sennosides tab 50 mg with sennosides 8 mg 

Brand change

  • Solax – new listing and addition of PSS (p’code 2712172)
  • Laxsol to be delisted 1 May 2026

Entrectinib (Rozlytrek) cap 200 mg

new listing (p’code 2599929)

Faricimab (Vabysmo) inj 120 mg per ml, 0.24 ml vial

new listing (p’code 2666715)

Ferrous fumarate (Ferro-tab) tab 200 mg (65.7 mg elemental)

amended presentation description

Fulvestrant inj 50 mg per ml, 5 ml prefilled syringe 

 

Brand change

  • Fulvestrant EVER Pharma –
    new listing and addition of PSS (p’code 2663139)
  • Faslodex to be delisted 1 May 2026

Heparin sodium (Wockhardt) inj 10 iu per ml, 5 ml ampoule (flushing solution) 

new listing (p’code 2717840)

Isoniazid with rifampicin (Rifamazid) tab 100 mg with rifampicin 150 mg 

new listing (p’code 2718243)

Long-Acting Muscarinic Antagonists with
Long-Acting Beta-Adrenoceptor Agonists

amended restriction criteria

Lopinavir with ritonavir oral liq 80 mg per ml with
ritonavir 20 mg per ml

new listing

Lopinavir with ritonavir (Lopinavir/Ritonavir Mylan) tab 100 mg with ritonavir 25 mg

brand only delisted 1 December 2025

Methylphenidate hydrochloride (Methylphenidate Sandoz XR) tab modified-release 18 mg, 27 mg, 36 mg and 54 mg

new listing

  • Tab modified-release 18 mg (p’code 2711176)
  • Tab modified-release 27 mg (p’code 2711184)
  • Tab modified-release 36 mg (p’code 2711192)
  • Tab modified-release 54 mg (p’code 2711206)

Methylphenidate hydrochloride (Methylphenidate ER – Teva) tab extended-release 18 mg, 27 mg, 36 mg and 54 mg

price increase

Methylphenidate hydrochloride

  • Tab extended-release 18 mg, 27 mg, 36 mg and 54 mg (Concerta and
    Methylphenidate ER – Teva)
  • Tab immediate-release 5 mg, 10 mg and 20 mg (Rubifen)
  • Tab immediate-release 10 mg (Ritalin)
  • Tab sustained-release 20 mg (Rubifen SR)
  • Tab modified-release 18 mg, 27 mg, 36 mg and 54 mg (Methylphenidate Sandoz XR)
  • Cap modified-release 10 mg, 20 mg, 30 mg and 40 mg (Ritalin LA)

amended restriction criteria

Mitomycin C (Teva) inj 20 mg vial

price decrease and addition of PSS

Obinutuzumab (Gazyva) inj 25 mg per ml, 40 ml vial

amended restriction criteria

Ocrelizumab (Ocrevus SC) inj 40 mg per ml, 23 ml vial

new listing (p’code 2717441)

Ocrelizumab (Ocrevus) inj 30 mg per ml, 10 ml vial

price decrease

Oxycodone hydrochloride oral liq 1 mg per ml, 250 ml

Brand change

  • Rosemont – new listing (p’code 2717239)
  • Oxycodone Lucis S29 to be delisted 1 June 2026

Pantoprazole (Panzop Relief) tab EC 20 mg and 40 mg

price decrease and addition of PSS

Pembrolizumab (Keytruda) inj 25 mg per ml, 4 ml vial

amended restriction criteria

Pentamidine isethionate (Tillomed) inj 300 mg vial

new listing (p’code 2717328)

Pertuzumab with trastuzumab (Phesgo) inj 600 mg with trastuzumab 600 mg, 10 ml vial and inj 1,200 mg with trastuzumab 600 mg, 15 ml vial

new listing

  • Inj 600 mg with trastuzumab 600 mg, 10 ml vial (p’code 2649373)
  • Inj 1,200 mg with trastuzumab 600 mg, 15 ml vial (p’code 2649381)

Phytomenadione (Konakion MM Paediatric) inj 2 mg in 0.2 ml ampoule 

Pharmacode 2703572 to be delisted 1
February 2026

Potassium chloride (Span-K) tab long-acting 600 mg (8 mmol)

new Pharmacode listing (p’code 2717700)

Ranibizumab inj 10 mg per ml, 0.23 ml vial and 0.3 ml vial

amended restriction criteria 

Rituximab (Mabthera) inj 100 mg per 10 ml vial and inj 500 mg per 50 ml vial 

amended restriction criteria

Rosuvastatin (Rosuvastatin-Sandoz) tab 20 mg

new listing (p’code 2716739)

Salbutamol (Ventolin) aerosol inhaler, 100 mcg per dose, 200 dose

price increase

Silver diamine fluoride (Topamine) oral application 38%, 5 ml

new listing (p’code 2718472)

Somatropin (Omnitrope AU) inj 5 mg cartridge 

new listing (p’code 2648415)

Sotalol (Sotalol Viatris) tab 80 mg

to be delisted 1 March 2026

Sunitinib cap 50 mg

 

Brand change

  • Sunitinib Rex – new listing and
    addition of PSS (p’code 2675498)
  • Sunitinib Pfizer to be delisted 1 May 2026

Tranexamic acid (Mercury Pharma) tab 500 mg

price decrease and addition of PSS

Trametinib (Mekinist) tab 0.5 mg and 2 mg

amended restriction criteria

Vancomycin inj 500 mg vial

 

Brand change

  • Vancomycin Viatris – new listing (p’code 2696282)
  • Mylan to be delisted 1 March 2026

 

Find previous months' summaries